image credit- Syntellix
The Central Drugs Standard Control Organisation (CDSCO) has granted German firm Syntellix the license to bring five different product families of its revolutionary bioabsorbable magnesium-based implants to market.
In one fell swoop, this increases global market access and the amount of potential patients who can be treated with the company's MAGNEZIX® implants by an additional 1.38 billion to now 3.8 billion people.
The game-changer market of India, with its exceptionally good doctors and in many cases ultra-modern hospitals, plays a decisive role in the global substitution of conventional implant technologies in favour of the MAGNEZIX® platform technology.
In addition, India is ideally suited for collecting further clinical data and conducting clinical trials and will also contribute significantly to the development of new, additional Syntellix products.
